Our Studies
Tenaya’s Research In Hypertrophic Cardiomyopathy (HCM)
Tenaya Therapeutics is a clinical-stage biotechnology company using knowledge of genetics to discover and develop new medicines that may transform and extend the lives of people with heart disease.
Learn about Tenaya’s efforts to better understand and characterize MYBPC3-associated HCM, as well as the first clinical trial to study TN-201 as a potential treatment for MYBPC3-associated HCM.
A Phase 1b clinical trial of an investigational gene therapy called TN-201 for the treatment of HCM caused by mutations in the MYBPC3 gene.
A natural history study designed to collect and evaluate information on how cardiomyopathy changes over time in infants, children, and teens with the MYBPC3 gene mutation. This study only involves review of your medical records and blood draw.
Complete this form or contact patient.advocacy@tenayathera.com or clinical.trials@tenayathera.com for more information about:
- HCM and genetic testing
- Where to take part in research for MYBPC3-associated HCM
- Tenaya’s science
